<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT00077454">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00077454">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT00077454 on 2013_06_04</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Protocol, Recruitment, Location/Contact, Administrative, Misc.</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00077454/2012_12_14/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00077454/2012_12_14">(Updated 2012_12_14)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><span class="nolink" title="There is no version after this one."><img src="/archive/next-g.gif" alt="" width="23" height="19" /></span></div><h2>After</h2><h3><a href="/archive/NCT00077454/2013_06_04">(Updated 2013_06_04)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NCI</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Cancer Institute (NCI)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  NCI-2012-01808</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  ADVL0214</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
</div><div class="sdl3 sds">&lt;id&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NCI</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Cancer Institute (NCI)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  NCI-2012-01808</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  ADVL0214</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
</div><div class="sdl3 sds">&lt;id&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl4"><span class="sdwc">U01CA097452</span> </div>
</td>
<td class="sdiff-b"><div class="sdl4"><span class="sdwc">CDR0000350336</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><div class="sdl3 sdz">&lt;/id&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3 sdz">&lt;/id&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  US NIH Grant Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-f6"><td class="sdiff-h">6</td>
<td class="sdiff-a"><div class="sdl4">  CDR0000350336</div>
</td>
<td class="sdiff-b"><div class="sdl4"></div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-f7"><td class="sdiff-h">7</td>
<td class="sdiff-a"><div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
</td>
<td class="sdiff-b"><div class="sdl4">  COG-ADVL0214</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  NCI-04-C-0256</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  U01CA097452</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f8"><td class="sdiff-h">8</td>
<td class="sdiff-a"><div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f9"><td class="sdiff-h">9</td>
<td class="sdiff-a"><div class="sdl4"><span class="sdwd">Registry</span> <span class="sdwd">Identifier</span>     </div>
</td>
<td class="sdiff-b"><div class="sdl4">  <span class="sdwa">US</span> <span class="sdwa">NIH</span> <span class="sdwa">Grant</span> <span class="sdwa">Number</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f10"><td class="sdiff-h">10</td>
<td class="sdiff-a"><div class="sdl3 sdz">&lt;/id_type&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3 sdz">&lt;/id_type&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-f11"><td class="sdiff-h">11</td>
<td class="sdiff-a"><div class="sdl3 sds">&lt;id_domain&gt;</div>
<div class="sdl4">  PDQ (Physician Data Query)</div>
<div class="sdl3 sdz">&lt;/id_domain&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f12"><td class="sdiff-h">12</td>
<td class="sdiff-a"><img id="sdiff-collapse-f45A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f45&#39;)" style="display:none" /><img id="sdiff-collapse-f45A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f45&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div id="sdiff-collapse-f45A-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f45&#39;)" style="display:none"></div><div id="sdiff-collapse-f45A-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00077454</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f45B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f45&#39;)" style="display:none" /><img id="sdiff-collapse-f45B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f45&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div id="sdiff-collapse-f45B-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f45&#39;)" style="display:none"></div><div id="sdiff-collapse-f45B-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00077454</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f13"><td class="sdiff-h">13</td>
<td class="sdiff-a"><div class="sdl3">A <span class="sdwc">PHASE</span> I <span class="sdwc">STUDY</span> <span class="sdwc">OF</span> <span class="sdwc">SINGLE</span> <span class="sdwc">AGENT</span> OSI-774 <span class="sdwd">(TARCEVA)</span> <span class="sdwd">(NSC</span> <span class="sdwd">#</span>   718781, <span class="sdwc">IND</span> <span class="sdwc">#63383)</span> <span class="sdwc">FOLLOWED</span> <span class="sdwc">BY</span> OSI-774 <span class="sdwc">WITH</span> <span class="sdwc">TEMOZOLOMIDE</span> <span class="sdwc">FOR</span> <span class="sdwc">PATIENTS</span> <span class="sdwc">WITH</span> <span class="sdwc">SELECTED</span> <span class="sdwc">RECURRENT/REFRACTORY</span> <span class="sdwc">SOLID</span> <span class="sdwc">TUMORS,</span> <span class="sdwc">INCLUDING</span> <span class="sdwc">BRAIN</span> <span class="sdwc">TUMORS</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3">A  <span class="sdwc">Phase</span> I  <span class="sdwc">Study</span> <span class="sdwc">of</span> <span class="sdwc">Single</span> <span class="sdwc">Agent</span> OSI-774     <span class="sdwa">(Tarceva)</span> <span class="sdwa">(NSC#</span> 718781,  <span class="sdwc">IND#</span> <span class="sdwc">63383)</span> <span class="sdwc">Followed</span> <span class="sdwc">by</span> OSI-774  <span class="sdwc">With</span> <span class="sdwc">Temozolomide</span> <span class="sdwc">for</span> <span class="sdwc">Patients</span> <span class="sdwc">With</span> <span class="sdwc">Selected</span> <span class="sdwc">Recurrent/Refractory</span> <span class="sdwc">Solid</span> <span class="sdwc">Tumors,</span> <span class="sdwc">Including</span> <span class="sdwc">Brain</span> <span class="sdwc">Tumors</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f14"><td class="sdiff-h">14</td>
<td class="sdiff-a"><img id="sdiff-collapse-f64A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f64&#39;)" style="display:none" /><img id="sdiff-collapse-f64A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f64&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-f64A-cdiv" class="sdiff-collapsed" title="The middle 24 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f64&#39;)" style="display:none"></div><div id="sdiff-collapse-f64A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f64B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f64&#39;)" style="display:none" /><img id="sdiff-collapse-f64B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f64&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-f64B-cdiv" class="sdiff-collapsed" title="The middle 24 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f64&#39;)" style="display:none"></div><div id="sdiff-collapse-f64B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f15"><td class="sdiff-h">15</td>
<td class="sdiff-a"><div class="sdl3">This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor <span class="sdwc">cells</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3">This  phase  I  trial  is  studying  the  side  effects  and  best  dose  of  erlotinib  when  given  with  temozolomide  in  treating  young  patients  with  recurrent  or  refractory  solid  tumors.  Erlotinib  may  stop  the  growth  of  tumor  cells  by  blocking  the  enzymes  necessary  for  their  growth.  Drugs  used  in  chemotherapy,  such  as  temozolomide,  work  in  different  ways  to  stop  tumor  cells  from  dividing  so  they  stop  growing  or  die.  Giving  erlotinib  with  temozolomide  may  kill  more  tumor  <span class="sdwc">cells.</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f16"><td class="sdiff-h">16</td>
<td class="sdiff-a"><img id="sdiff-collapse-f91A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f91&#39;)" style="display:none" /><img id="sdiff-collapse-f91A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f91&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-f91A-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f91&#39;)" style="display:none"></div><div id="sdiff-collapse-f91A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  PRIMARY OBJECTIVES:</div>
<div class="sdl3">  I. Determine the maximum tolerated dose of erlotinib in children with recurrent or refractory solid tumors.</div>
<div class="sdl3">  II. Determine the dose-limiting toxic effects of this drug alone and with temozolomide in these patients.</div>
<div class="sdl3">  III. Determine the tolerability of this regimen in these patients.</div>
<div class="sdl3">  IV. Determine the pharmacokinetics of this regimen in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  SECONDARY OBJECTIVES:</div>
<div class="sdl3">  I. Determine, preliminarily, the antitumor activity of this regimen in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  OUTLINE: This is a 2-part, multicenter, dose-escalation study of erlotinib. Patients are stratified according to pretreatment (heavily pretreated [received more than 2 prior multiagent myelosuppressive chemotherapy regimens OR received prior craniospinal or pelvic radiotherapy or bone marrow transplantation OR has bone marrow involvement] vs less heavily pretreated).Part 1: </div>
<div class="sdl3">  </div>
<div class="sdl3">  Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Cohorts of 3-6 patients receive escalating doses of erlotinib during course 1 only until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Part 2: Patients receive erlotinib (at the MTD) and temozolomide as in part 1. </div>
<div class="sdl3">  </div>
<div class="sdl3">  PROJECTED ACCRUAL: A total of 9-45 patients (9-24 for part 1 and up to 21 for part 2) will be accrued for this study.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f91B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f91&#39;)" style="display:none" /><img id="sdiff-collapse-f91B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f91&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-f91B-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f91&#39;)" style="display:none"></div><div id="sdiff-collapse-f91B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  PRIMARY OBJECTIVES:</div>
<div class="sdl3">  I. Determine the maximum tolerated dose of erlotinib in children with recurrent or refractory solid tumors.</div>
<div class="sdl3">  II. Determine the dose-limiting toxic effects of this drug alone and with temozolomide in these patients.</div>
<div class="sdl3">  III. Determine the tolerability of this regimen in these patients.</div>
<div class="sdl3">  IV. Determine the pharmacokinetics of this regimen in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  SECONDARY OBJECTIVES:</div>
<div class="sdl3">  I. Determine, preliminarily, the antitumor activity of this regimen in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  OUTLINE: This is a 2-part, multicenter, dose-escalation study of erlotinib. Patients are stratified according to pretreatment (heavily pretreated [received more than 2 prior multiagent myelosuppressive chemotherapy regimens OR received prior craniospinal or pelvic radiotherapy or bone marrow transplantation OR has bone marrow involvement] vs less heavily pretreated).Part 1: </div>
<div class="sdl3">  </div>
<div class="sdl3">  Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Cohorts of 3-6 patients receive escalating doses of erlotinib during course 1 only until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Part 2: Patients receive erlotinib (at the MTD) and temozolomide as in part 1. </div>
<div class="sdl3">  </div>
<div class="sdl3">  PROJECTED ACCRUAL: A total of 9-45 patients (9-24 for part 1 and up to 21 for part 2) will be accrued for this study.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f17"><td class="sdiff-h">17</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2012-12</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2013-06</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f18"><td class="sdiff-h">18</td>
<td class="sdiff-a"><img id="sdiff-collapse-f121A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f121&#39;)" style="display:none" /><img id="sdiff-collapse-f121A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f121&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f121A-cdiv" class="sdiff-collapsed" title="The middle 9 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f121&#39;)" style="display:none"></div><div id="sdiff-collapse-f121A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2004-02</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Actual&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f121B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f121&#39;)" style="display:none" /><img id="sdiff-collapse-f121B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f121&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f121B-cdiv" class="sdiff-collapsed" title="The middle 9 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f121&#39;)" style="display:none"></div><div id="sdiff-collapse-f121B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2004-02</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Actual&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f19"><td class="sdiff-h">19</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2006-04</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2007-09</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f20"><td class="sdiff-h">20</td>
<td class="sdiff-a"><img id="sdiff-collapse-f133A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f133&#39;)" style="display:none" /><img id="sdiff-collapse-f133A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f133&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f133A-cdiv" class="sdiff-collapsed" title="The middle 284 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f133&#39;)" style="display:none"></div><div id="sdiff-collapse-f133A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  1</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  56 days (2 courses)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  56 days (2 courses)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Pharmacokinetics of erlotinib hydrochloride</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At baseline and at 0.5, 1, 2, 4, 6, 8, and 24 hours of course 1</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Actual&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  95</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Previously Treated Childhood Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Brain Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Cerebellar Astrocytoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Cerebral Astrocytoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Ependymoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Malignant Germ Cell Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Medulloblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Soft Tissue Sarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Neuroblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Osteosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  erlotinib hydrochloride</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Given orally (PO)</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  CP-358,774</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  erlotinib</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  OSI-774</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  temozolomide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Given PO</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  SCH 52365</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Temodal</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Temodar</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  TMZ</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  pharmacological study</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Correlative studies</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  pharmacological studies</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  laboratory biomarker analysis</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Correlative studies</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria: </div>
<div class="sdl4">    - One of the following histologically confirmed solid tumors:            </div>
<div class="sdl4">    * Brain tumors</div>
<div class="sdl4">    * Osteogenic sarcoma</div>
<div class="sdl4">    * Rhabdomyosarcoma</div>
<div class="sdl4">    * Soft tissue sarcoma (excluding Ewing&amp;apos;s sarcoma)</div>
<div class="sdl4">    * Neuroblastoma</div>
<div class="sdl4">    * Germ cell tumors</div>
<div class="sdl4">    - Recurrent or refractory disease</div>
<div class="sdl4">    - No known curative therapy exists</div>
<div class="sdl4">    - Performance status - Karnofsky 50-100% (for patients age 11 to 21)</div>
<div class="sdl4">    - Performance status - Lansky 50-100% (for patients age 10 and under)</div>
<div class="sdl4">    - At least 8 weeks</div>
<div class="sdl4">    - Absolute neutrophil count &amp;gt; 1,000/mm^3</div>
<div class="sdl4">    - Platelet count &amp;gt; 100,000/mm^3 (transfusion independent*)</div>
<div class="sdl4">    - Hemoglobin &amp;gt; 8.0 g/dL (transfusion allowed)</div>
<div class="sdl4">    - Bilirubin &amp;lt; 1.5 times upper limit of normal (ULN)</div>
<div class="sdl4">    - ALT &amp;lt; 2.5 times ULN</div>
<div class="sdl4">    - Albumin &amp;#8805; 2 g/dL</div>
<div class="sdl4">    - Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min</div>
<div class="sdl4">    - Creatinine based on age as follows:            </div>
<div class="sdl4">    * &amp;#8804; 0.8 mg/dL for patients age 5 and under</div>
<div class="sdl4">    * &amp;#8804; 1.0 mg/dL for patients 6 to 10</div>
<div class="sdl4">    * &amp;#8804; 1.2 mg/dL for patients 11 to 15</div>
<div class="sdl4">    * &amp;#8804; 1.5 mg/dL for patients age 15 to 21</div>
<div class="sdl4">    - Not pregnant or nursing</div>
<div class="sdl4">    - Negative pregnancy test</div>
<div class="sdl4">    - Fertile patients must use effective contraception</div>
<div class="sdl4">    - Able to swallow tablets (for patients in part 2 only)</div>
<div class="sdl4">    - No uncontrolled infection</div>
<div class="sdl4">    - Recovered from all prior immunotherapy</div>
<div class="sdl4">    - At least 7 days since prior biologic therapy</div>
<div class="sdl4">    - At least 3 months since prior stem cell transplantation and no evidence of active graft-versus-host disease</div>
<div class="sdl4">    - More than 1 week since prior growth factors</div>
<div class="sdl4">    - No concurrent prophylactic growth factor therapy</div>
<div class="sdl4">    - No concurrent immunotherapy</div>
<div class="sdl4">    - No concurrent biologic therapy</div>
<div class="sdl4">    - More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered</div>
<div class="sdl4">    - No other concurrent chemotherapy</div>
<div class="sdl4">    - No concurrent systemic corticosteroids except for treatment of increased intracranial pressure or symptomatic tumor edema in patients with CNS tumors            </div>
<div class="sdl4">    * No concurrent steroids as an antiemetic</div>
<div class="sdl4">    - Concurrent dexamethasone for patients with CNS tumors allowed provided patient has been on a stable or decreasing dose for at least 1 week before study entry</div>
<div class="sdl4">    - Recovered from all prior radiotherapy</div>
<div class="sdl4">    - At least 2 weeks since prior local palliative radiotherapy (small port)</div>
<div class="sdl4">    - At least 6 weeks since prior substantial bone marrow irradiation</div>
<div class="sdl4">    - At least 6 months since prior craniospinal radiotherapy</div>
<div class="sdl4">    - At least 6 months since prior radiotherapy to 50% or more of the pelvis</div>
<div class="sdl4">    - At least 8 weeks since prior standard-fraction radiotherapy for patients with recurrent brain tumors unless there is biopsy proof of recurrent tumor</div>
<div class="sdl4">    - Prior radiosurgery within the past 9 months allowed provided there is documentation of progressive disease by biopsy, positron-emission tomography (PET) scan, or MR spectroscopy</div>
<div class="sdl4">    - No concurrent radiotherapy</div>
<div class="sdl4">    - More than 1 week since prior CYP3A4 inhibitors</div>
<div class="sdl4">    - More than 4 weeks since prior CYP3A4 inducers</div>
<div class="sdl4">    - More than 5 days since prior proton-pump inhibitors</div>
<div class="sdl4">    - More than 2 days since prior H_2 blockers</div>
<div class="sdl4">    - No prior erlotinib</div>
<div class="sdl4">    - No concurrent enzyme-inducing anticonvulsants</div>
<div class="sdl4">    - No concurrent proton-pump inhibitors</div>
<div class="sdl4">    - No concurrent H2 blockers</div>
<div class="sdl4">    - No other concurrent investigational agents</div>
<div class="sdl4">    - Concurrent antacids allowed provided the antacid is not administered 2 hours before, during, and 2 hours after erlotinib administration</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  21 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Regina Jakacki</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
</div><div class="sdl3 sds">&lt;agency&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f133B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f133&#39;)" style="display:none" /><img id="sdiff-collapse-f133B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f133&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f133B-cdiv" class="sdiff-collapsed" title="The middle 284 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f133&#39;)" style="display:none"></div><div id="sdiff-collapse-f133B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  1</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  56 days (2 courses)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  56 days (2 courses)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Pharmacokinetics of erlotinib hydrochloride</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At baseline and at 0.5, 1, 2, 4, 6, 8, and 24 hours of course 1</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Actual&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  95</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Previously Treated Childhood Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Brain Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Cerebellar Astrocytoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Cerebral Astrocytoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Ependymoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Malignant Germ Cell Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Medulloblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Soft Tissue Sarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Neuroblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Osteosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  erlotinib hydrochloride</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Given orally (PO)</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  CP-358,774</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  erlotinib</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  OSI-774</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  temozolomide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Given PO</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  SCH 52365</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Temodal</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Temodar</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  TMZ</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  pharmacological study</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Correlative studies</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  pharmacological studies</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  laboratory biomarker analysis</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Correlative studies</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria: </div>
<div class="sdl4">    - One of the following histologically confirmed solid tumors:            </div>
<div class="sdl4">    * Brain tumors</div>
<div class="sdl4">    * Osteogenic sarcoma</div>
<div class="sdl4">    * Rhabdomyosarcoma</div>
<div class="sdl4">    * Soft tissue sarcoma (excluding Ewing&amp;apos;s sarcoma)</div>
<div class="sdl4">    * Neuroblastoma</div>
<div class="sdl4">    * Germ cell tumors</div>
<div class="sdl4">    - Recurrent or refractory disease</div>
<div class="sdl4">    - No known curative therapy exists</div>
<div class="sdl4">    - Performance status - Karnofsky 50-100% (for patients age 11 to 21)</div>
<div class="sdl4">    - Performance status - Lansky 50-100% (for patients age 10 and under)</div>
<div class="sdl4">    - At least 8 weeks</div>
<div class="sdl4">    - Absolute neutrophil count &amp;gt; 1,000/mm^3</div>
<div class="sdl4">    - Platelet count &amp;gt; 100,000/mm^3 (transfusion independent*)</div>
<div class="sdl4">    - Hemoglobin &amp;gt; 8.0 g/dL (transfusion allowed)</div>
<div class="sdl4">    - Bilirubin &amp;lt; 1.5 times upper limit of normal (ULN)</div>
<div class="sdl4">    - ALT &amp;lt; 2.5 times ULN</div>
<div class="sdl4">    - Albumin &amp;#8805; 2 g/dL</div>
<div class="sdl4">    - Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min</div>
<div class="sdl4">    - Creatinine based on age as follows:            </div>
<div class="sdl4">    * &amp;#8804; 0.8 mg/dL for patients age 5 and under</div>
<div class="sdl4">    * &amp;#8804; 1.0 mg/dL for patients 6 to 10</div>
<div class="sdl4">    * &amp;#8804; 1.2 mg/dL for patients 11 to 15</div>
<div class="sdl4">    * &amp;#8804; 1.5 mg/dL for patients age 15 to 21</div>
<div class="sdl4">    - Not pregnant or nursing</div>
<div class="sdl4">    - Negative pregnancy test</div>
<div class="sdl4">    - Fertile patients must use effective contraception</div>
<div class="sdl4">    - Able to swallow tablets (for patients in part 2 only)</div>
<div class="sdl4">    - No uncontrolled infection</div>
<div class="sdl4">    - Recovered from all prior immunotherapy</div>
<div class="sdl4">    - At least 7 days since prior biologic therapy</div>
<div class="sdl4">    - At least 3 months since prior stem cell transplantation and no evidence of active graft-versus-host disease</div>
<div class="sdl4">    - More than 1 week since prior growth factors</div>
<div class="sdl4">    - No concurrent prophylactic growth factor therapy</div>
<div class="sdl4">    - No concurrent immunotherapy</div>
<div class="sdl4">    - No concurrent biologic therapy</div>
<div class="sdl4">    - More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered</div>
<div class="sdl4">    - No other concurrent chemotherapy</div>
<div class="sdl4">    - No concurrent systemic corticosteroids except for treatment of increased intracranial pressure or symptomatic tumor edema in patients with CNS tumors            </div>
<div class="sdl4">    * No concurrent steroids as an antiemetic</div>
<div class="sdl4">    - Concurrent dexamethasone for patients with CNS tumors allowed provided patient has been on a stable or decreasing dose for at least 1 week before study entry</div>
<div class="sdl4">    - Recovered from all prior radiotherapy</div>
<div class="sdl4">    - At least 2 weeks since prior local palliative radiotherapy (small port)</div>
<div class="sdl4">    - At least 6 weeks since prior substantial bone marrow irradiation</div>
<div class="sdl4">    - At least 6 months since prior craniospinal radiotherapy</div>
<div class="sdl4">    - At least 6 months since prior radiotherapy to 50% or more of the pelvis</div>
<div class="sdl4">    - At least 8 weeks since prior standard-fraction radiotherapy for patients with recurrent brain tumors unless there is biopsy proof of recurrent tumor</div>
<div class="sdl4">    - Prior radiosurgery within the past 9 months allowed provided there is documentation of progressive disease by biopsy, positron-emission tomography (PET) scan, or MR spectroscopy</div>
<div class="sdl4">    - No concurrent radiotherapy</div>
<div class="sdl4">    - More than 1 week since prior CYP3A4 inhibitors</div>
<div class="sdl4">    - More than 4 weeks since prior CYP3A4 inducers</div>
<div class="sdl4">    - More than 5 days since prior proton-pump inhibitors</div>
<div class="sdl4">    - More than 2 days since prior H_2 blockers</div>
<div class="sdl4">    - No prior erlotinib</div>
<div class="sdl4">    - No concurrent enzyme-inducing anticonvulsants</div>
<div class="sdl4">    - No concurrent proton-pump inhibitors</div>
<div class="sdl4">    - No concurrent H2 blockers</div>
<div class="sdl4">    - No other concurrent investigational agents</div>
<div class="sdl4">    - Concurrent antacids allowed provided the antacid is not administered 2 hours before, during, and 2 hours after erlotinib administration</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  21 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Regina Jakacki</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
</div><div class="sdl3 sds">&lt;agency&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f21"><td class="sdiff-h">21</td>
<td class="sdiff-a"><div class="sdl4"><span class="sdwd">Children&amp;apos;s</span> <span class="sdwd">Oncology</span> <span class="sdwd">Group</span>     </div>
</td>
<td class="sdiff-b"><div class="sdl4">   <span class="sdwa">COG</span> <span class="sdwa">Phase</span> <span class="sdwa">I</span> <span class="sdwa">Consortium</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f22"><td class="sdiff-h">22</td>
<td class="sdiff-a"><img id="sdiff-collapse-f420A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f420&#39;)" style="display:none" /><img id="sdiff-collapse-f420A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f420&#39;)" style="display:none" /><div class="sdl3 sdz">&lt;/agency&gt;</div>
<div id="sdiff-collapse-f420A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f420&#39;)" style="display:none"></div><div id="sdiff-collapse-f420A-ediv" class="sdiff-expanded"><div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
</div><div class="sdl3 sds">&lt;name&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f420B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f420&#39;)" style="display:none" /><img id="sdiff-collapse-f420B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f420&#39;)" style="display:none" /><div class="sdl3 sdz">&lt;/agency&gt;</div>
<div id="sdiff-collapse-f420B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f420&#39;)" style="display:none"></div><div id="sdiff-collapse-f420B-ediv" class="sdiff-expanded"><div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
</div><div class="sdl3 sds">&lt;name&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f23"><td class="sdiff-h">23</td>
<td class="sdiff-a"><div class="sdl4"><span class="sdwd">Children&amp;apos;s</span> <span class="sdwd">Oncology</span> <span class="sdwd">Group</span>     </div>
</td>
<td class="sdiff-b"><div class="sdl4">   <span class="sdwa">COG</span> <span class="sdwa">Phase</span> <span class="sdwa">I</span> <span class="sdwa">Consortium</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f24"><td class="sdiff-h">24</td>
<td class="sdiff-a"><img id="sdiff-collapse-f427A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f427&#39;)" style="display:none" /><img id="sdiff-collapse-f427A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f427&#39;)" style="display:none" /><div class="sdl3 sdz">&lt;/name&gt;</div>
<div id="sdiff-collapse-f427A-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f427&#39;)" style="display:none"></div><div id="sdiff-collapse-f427A-ediv" class="sdiff-expanded"><div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Arcadia</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  California</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  91006-3776</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Regina I. Jakacki</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  412-692-7056</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
</div><div class="sdl3 sds">&lt;email&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f427B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f427&#39;)" style="display:none" /><img id="sdiff-collapse-f427B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f427&#39;)" style="display:none" /><div class="sdl3 sdz">&lt;/name&gt;</div>
<div id="sdiff-collapse-f427B-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f427&#39;)" style="display:none"></div><div id="sdiff-collapse-f427B-ediv" class="sdiff-expanded"><div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Arcadia</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  California</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  91006-3776</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Regina I. Jakacki</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  412-692-7056</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
</div><div class="sdl3 sds">&lt;email&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f25"><td class="sdiff-h">25</td>
<td class="sdiff-a"><div class="sdl4"><span class="sdwc">regina.jakacki@chp.edu</span> </div>
</td>
<td class="sdiff-b"><div class="sdl4"><span class="sdwc">Regina.Jakacki@chp.edu</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f26"><td class="sdiff-h">26</td>
<td class="sdiff-a"><img id="sdiff-collapse-f457A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f457&#39;)" style="display:none" /><img id="sdiff-collapse-f457A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f457&#39;)" style="display:none" /><div class="sdl3 sdz">&lt;/email&gt;</div>
<div id="sdiff-collapse-f457A-cdiv" class="sdiff-collapsed" title="The middle 13 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f457&#39;)" style="display:none"></div><div id="sdiff-collapse-f457A-ediv" class="sdiff-expanded"><div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Regina I. Jakacki</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2004-02-10</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f457B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f457&#39;)" style="display:none" /><img id="sdiff-collapse-f457B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f457&#39;)" style="display:none" /><div class="sdl3 sdz">&lt;/email&gt;</div>
<div id="sdiff-collapse-f457B-cdiv" class="sdiff-collapsed" title="The middle 13 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f457&#39;)" style="display:none"></div><div id="sdiff-collapse-f457B-ediv" class="sdiff-expanded"><div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Regina I. Jakacki</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2004-02-10</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f27"><td class="sdiff-h">27</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2012-12-13</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2013-06-04</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f28"><td class="sdiff-h">28</td>
<td class="sdiff-a"><img id="sdiff-collapse-f473A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f473&#39;)" style="display:none" /><img id="sdiff-collapse-f473A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f473&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f473A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f473&#39;)" style="display:none"></div><div id="sdiff-collapse-f473A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f473B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f473&#39;)" style="display:none" /><img id="sdiff-collapse-f473B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f473&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f473B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f473&#39;)" style="display:none"></div><div id="sdiff-collapse-f473B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00077454/2012_12_14/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00077454/2012_12_14">(Updated 2012_12_14)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><span class="nolink" title="There is no version after this one."><img src="/archive/next-g.gif" alt="" width="23" height="19" /></span></div><h2>After</h2><h3><a href="/archive/NCT00077454/2013_06_04">(Updated 2013_06_04)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NCI</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Cancer Institute (NCI)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  NCI-2012-01808</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  ADVL0214</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
</div><div class="sdl3 sds">&lt;id&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NCI</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Cancer Institute (NCI)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  NCI-2012-01808</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  ADVL0214</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
</div><div class="sdl3 sds">&lt;id&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl4"><span class="sdwc">U01CA097452</span> </div>
</td>
<td class="sdiff-b"><div class="sdl4"><span class="sdwc">CDR0000350336</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><div class="sdl3 sdz">&lt;/id&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3 sdz">&lt;/id&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  US NIH Grant Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-m6"><td class="sdiff-h">6</td>
<td class="sdiff-a"><div class="sdl4">  CDR0000350336</div>
</td>
<td class="sdiff-b"><div class="sdl4"></div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-m7"><td class="sdiff-h">7</td>
<td class="sdiff-a"><div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
</td>
<td class="sdiff-b"><div class="sdl4">  COG-ADVL0214</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  NCI-04-C-0256</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  U01CA097452</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m8"><td class="sdiff-h">8</td>
<td class="sdiff-a"><div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m9"><td class="sdiff-h">9</td>
<td class="sdiff-a"><div class="sdl4"><span class="sdwd">Registry</span> <span class="sdwd">Identifier</span>     </div>
</td>
<td class="sdiff-b"><div class="sdl4">  <span class="sdwa">US</span> <span class="sdwa">NIH</span> <span class="sdwa">Grant</span> <span class="sdwa">Number</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m10"><td class="sdiff-h">10</td>
<td class="sdiff-a"><div class="sdl3 sdz">&lt;/id_type&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3 sdz">&lt;/id_type&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-m11"><td class="sdiff-h">11</td>
<td class="sdiff-a"><div class="sdl3 sds">&lt;id_domain&gt;</div>
<div class="sdl4">  PDQ (Physician Data Query)</div>
<div class="sdl3 sdz">&lt;/id_domain&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m12"><td class="sdiff-h">12</td>
<td class="sdiff-a"><img id="sdiff-collapse-m45A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m45&#39;)" style="display:none" /><img id="sdiff-collapse-m45A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m45&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div id="sdiff-collapse-m45A-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m45&#39;)" style="display:none"></div><div id="sdiff-collapse-m45A-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00077454</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m45B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m45&#39;)" style="display:none" /><img id="sdiff-collapse-m45B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m45&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div id="sdiff-collapse-m45B-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m45&#39;)" style="display:none"></div><div id="sdiff-collapse-m45B-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00077454</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m13"><td class="sdiff-h">13</td>
<td class="sdiff-a"><div class="sdl3">A <span class="sdwc">PHASE</span> I <span class="sdwc">STUDY</span> <span class="sdwc">OF</span> <span class="sdwc">SINGLE</span> <span class="sdwc">AGENT</span> OSI-774 <span class="sdwd">(TARCEVA)</span> <span class="sdwd">(NSC</span> <span class="sdwd">#</span>   718781, <span class="sdwc">IND</span> <span class="sdwc">#63383)</span> <span class="sdwc">FOLLOWED</span> <span class="sdwc">BY</span> OSI-774 <span class="sdwc">WITH</span> <span class="sdwc">TEMOZOLOMIDE</span> <span class="sdwc">FOR</span> <span class="sdwc">PATIENTS</span> <span class="sdwc">WITH</span> <span class="sdwc">SELECTED</span> <span class="sdwc">RECURRENT/REFRACTORY</span> <span class="sdwc">SOLID</span> <span class="sdwc">TUMORS,</span> <span class="sdwc">INCLUDING</span> <span class="sdwc">BRAIN</span> <span class="sdwc">TUMORS</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3">A  <span class="sdwc">Phase</span> I  <span class="sdwc">Study</span> <span class="sdwc">of</span> <span class="sdwc">Single</span> <span class="sdwc">Agent</span> OSI-774     <span class="sdwa">(Tarceva)</span> <span class="sdwa">(NSC#</span> 718781,  <span class="sdwc">IND#</span> <span class="sdwc">63383)</span> <span class="sdwc">Followed</span> <span class="sdwc">by</span> OSI-774  <span class="sdwc">With</span> <span class="sdwc">Temozolomide</span> <span class="sdwc">for</span> <span class="sdwc">Patients</span> <span class="sdwc">With</span> <span class="sdwc">Selected</span> <span class="sdwc">Recurrent/Refractory</span> <span class="sdwc">Solid</span> <span class="sdwc">Tumors,</span> <span class="sdwc">Including</span> <span class="sdwc">Brain</span> <span class="sdwc">Tumors</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m14"><td class="sdiff-h">14</td>
<td class="sdiff-a"><img id="sdiff-collapse-m64A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m64&#39;)" style="display:none" /><img id="sdiff-collapse-m64A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m64&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-m64A-cdiv" class="sdiff-collapsed" title="The middle 24 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m64&#39;)" style="display:none"></div><div id="sdiff-collapse-m64A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m64B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m64&#39;)" style="display:none" /><img id="sdiff-collapse-m64B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m64&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-m64B-cdiv" class="sdiff-collapsed" title="The middle 24 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m64&#39;)" style="display:none"></div><div id="sdiff-collapse-m64B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m15"><td class="sdiff-h">15</td>
<td class="sdiff-a"><div class="sdl3">This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor <span class="sdwc">cells</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3">This  phase  I  trial  is  studying  the  side  effects  and  best  dose  of  erlotinib  when  given  with  temozolomide  in  treating  young  patients  with  recurrent  or  refractory  solid  tumors.  Erlotinib  may  stop  the  growth  of  tumor  cells  by  blocking  the  enzymes  necessary  for  their  growth.  Drugs  used  in  chemotherapy,  such  as  temozolomide,  work  in  different  ways  to  stop  tumor  cells  from  dividing  so  they  stop  growing  or  die.  Giving  erlotinib  with  temozolomide  may  kill  more  tumor  <span class="sdwc">cells.</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m16"><td class="sdiff-h">16</td>
<td class="sdiff-a"><img id="sdiff-collapse-m91A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m91&#39;)" style="display:none" /><img id="sdiff-collapse-m91A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m91&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-m91A-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m91&#39;)" style="display:none"></div><div id="sdiff-collapse-m91A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  PRIMARY OBJECTIVES:</div>
<div class="sdl3">  I. Determine the maximum tolerated dose of erlotinib in children with recurrent or refractory solid tumors.</div>
<div class="sdl3">  II. Determine the dose-limiting toxic effects of this drug alone and with temozolomide in these patients.</div>
<div class="sdl3">  III. Determine the tolerability of this regimen in these patients.</div>
<div class="sdl3">  IV. Determine the pharmacokinetics of this regimen in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  SECONDARY OBJECTIVES:</div>
<div class="sdl3">  I. Determine, preliminarily, the antitumor activity of this regimen in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  OUTLINE: This is a 2-part, multicenter, dose-escalation study of erlotinib. Patients are stratified according to pretreatment (heavily pretreated [received more than 2 prior multiagent myelosuppressive chemotherapy regimens OR received prior craniospinal or pelvic radiotherapy or bone marrow transplantation OR has bone marrow involvement] vs less heavily pretreated).Part 1: </div>
<div class="sdl3">  </div>
<div class="sdl3">  Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Cohorts of 3-6 patients receive escalating doses of erlotinib during course 1 only until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Part 2: Patients receive erlotinib (at the MTD) and temozolomide as in part 1. </div>
<div class="sdl3">  </div>
<div class="sdl3">  PROJECTED ACCRUAL: A total of 9-45 patients (9-24 for part 1 and up to 21 for part 2) will be accrued for this study.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m91B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m91&#39;)" style="display:none" /><img id="sdiff-collapse-m91B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m91&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-m91B-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m91&#39;)" style="display:none"></div><div id="sdiff-collapse-m91B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  PRIMARY OBJECTIVES:</div>
<div class="sdl3">  I. Determine the maximum tolerated dose of erlotinib in children with recurrent or refractory solid tumors.</div>
<div class="sdl3">  II. Determine the dose-limiting toxic effects of this drug alone and with temozolomide in these patients.</div>
<div class="sdl3">  III. Determine the tolerability of this regimen in these patients.</div>
<div class="sdl3">  IV. Determine the pharmacokinetics of this regimen in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  SECONDARY OBJECTIVES:</div>
<div class="sdl3">  I. Determine, preliminarily, the antitumor activity of this regimen in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  OUTLINE: This is a 2-part, multicenter, dose-escalation study of erlotinib. Patients are stratified according to pretreatment (heavily pretreated [received more than 2 prior multiagent myelosuppressive chemotherapy regimens OR received prior craniospinal or pelvic radiotherapy or bone marrow transplantation OR has bone marrow involvement] vs less heavily pretreated).Part 1: </div>
<div class="sdl3">  </div>
<div class="sdl3">  Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Cohorts of 3-6 patients receive escalating doses of erlotinib during course 1 only until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Part 2: Patients receive erlotinib (at the MTD) and temozolomide as in part 1. </div>
<div class="sdl3">  </div>
<div class="sdl3">  PROJECTED ACCRUAL: A total of 9-45 patients (9-24 for part 1 and up to 21 for part 2) will be accrued for this study.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m17"><td class="sdiff-h">17</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2012-12</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2013-06</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m18"><td class="sdiff-h">18</td>
<td class="sdiff-a"><img id="sdiff-collapse-m121A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m121&#39;)" style="display:none" /><img id="sdiff-collapse-m121A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m121&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m121A-cdiv" class="sdiff-collapsed" title="The middle 9 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m121&#39;)" style="display:none"></div><div id="sdiff-collapse-m121A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2004-02</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Actual&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m121B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m121&#39;)" style="display:none" /><img id="sdiff-collapse-m121B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m121&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m121B-cdiv" class="sdiff-collapsed" title="The middle 9 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m121&#39;)" style="display:none"></div><div id="sdiff-collapse-m121B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2004-02</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Actual&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m19"><td class="sdiff-h">19</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2006-04</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2007-09</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m20"><td class="sdiff-h">20</td>
<td class="sdiff-a"><img id="sdiff-collapse-m133A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m133&#39;)" style="display:none" /><img id="sdiff-collapse-m133A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m133&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m133A-cdiv" class="sdiff-collapsed" title="The middle 284 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m133&#39;)" style="display:none"></div><div id="sdiff-collapse-m133A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  1</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  56 days (2 courses)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  56 days (2 courses)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Pharmacokinetics of erlotinib hydrochloride</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At baseline and at 0.5, 1, 2, 4, 6, 8, and 24 hours of course 1</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Actual&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  95</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Previously Treated Childhood Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Brain Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Cerebellar Astrocytoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Cerebral Astrocytoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Ependymoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Malignant Germ Cell Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Medulloblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Soft Tissue Sarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Neuroblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Osteosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  erlotinib hydrochloride</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Given orally (PO)</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  CP-358,774</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  erlotinib</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  OSI-774</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  temozolomide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Given PO</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  SCH 52365</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Temodal</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Temodar</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  TMZ</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  pharmacological study</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Correlative studies</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  pharmacological studies</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  laboratory biomarker analysis</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Correlative studies</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria: </div>
<div class="sdl4">    - One of the following histologically confirmed solid tumors:            </div>
<div class="sdl4">    * Brain tumors</div>
<div class="sdl4">    * Osteogenic sarcoma</div>
<div class="sdl4">    * Rhabdomyosarcoma</div>
<div class="sdl4">    * Soft tissue sarcoma (excluding Ewing&amp;apos;s sarcoma)</div>
<div class="sdl4">    * Neuroblastoma</div>
<div class="sdl4">    * Germ cell tumors</div>
<div class="sdl4">    - Recurrent or refractory disease</div>
<div class="sdl4">    - No known curative therapy exists</div>
<div class="sdl4">    - Performance status - Karnofsky 50-100% (for patients age 11 to 21)</div>
<div class="sdl4">    - Performance status - Lansky 50-100% (for patients age 10 and under)</div>
<div class="sdl4">    - At least 8 weeks</div>
<div class="sdl4">    - Absolute neutrophil count &amp;gt; 1,000/mm^3</div>
<div class="sdl4">    - Platelet count &amp;gt; 100,000/mm^3 (transfusion independent*)</div>
<div class="sdl4">    - Hemoglobin &amp;gt; 8.0 g/dL (transfusion allowed)</div>
<div class="sdl4">    - Bilirubin &amp;lt; 1.5 times upper limit of normal (ULN)</div>
<div class="sdl4">    - ALT &amp;lt; 2.5 times ULN</div>
<div class="sdl4">    - Albumin &amp;#8805; 2 g/dL</div>
<div class="sdl4">    - Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min</div>
<div class="sdl4">    - Creatinine based on age as follows:            </div>
<div class="sdl4">    * &amp;#8804; 0.8 mg/dL for patients age 5 and under</div>
<div class="sdl4">    * &amp;#8804; 1.0 mg/dL for patients 6 to 10</div>
<div class="sdl4">    * &amp;#8804; 1.2 mg/dL for patients 11 to 15</div>
<div class="sdl4">    * &amp;#8804; 1.5 mg/dL for patients age 15 to 21</div>
<div class="sdl4">    - Not pregnant or nursing</div>
<div class="sdl4">    - Negative pregnancy test</div>
<div class="sdl4">    - Fertile patients must use effective contraception</div>
<div class="sdl4">    - Able to swallow tablets (for patients in part 2 only)</div>
<div class="sdl4">    - No uncontrolled infection</div>
<div class="sdl4">    - Recovered from all prior immunotherapy</div>
<div class="sdl4">    - At least 7 days since prior biologic therapy</div>
<div class="sdl4">    - At least 3 months since prior stem cell transplantation and no evidence of active graft-versus-host disease</div>
<div class="sdl4">    - More than 1 week since prior growth factors</div>
<div class="sdl4">    - No concurrent prophylactic growth factor therapy</div>
<div class="sdl4">    - No concurrent immunotherapy</div>
<div class="sdl4">    - No concurrent biologic therapy</div>
<div class="sdl4">    - More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered</div>
<div class="sdl4">    - No other concurrent chemotherapy</div>
<div class="sdl4">    - No concurrent systemic corticosteroids except for treatment of increased intracranial pressure or symptomatic tumor edema in patients with CNS tumors            </div>
<div class="sdl4">    * No concurrent steroids as an antiemetic</div>
<div class="sdl4">    - Concurrent dexamethasone for patients with CNS tumors allowed provided patient has been on a stable or decreasing dose for at least 1 week before study entry</div>
<div class="sdl4">    - Recovered from all prior radiotherapy</div>
<div class="sdl4">    - At least 2 weeks since prior local palliative radiotherapy (small port)</div>
<div class="sdl4">    - At least 6 weeks since prior substantial bone marrow irradiation</div>
<div class="sdl4">    - At least 6 months since prior craniospinal radiotherapy</div>
<div class="sdl4">    - At least 6 months since prior radiotherapy to 50% or more of the pelvis</div>
<div class="sdl4">    - At least 8 weeks since prior standard-fraction radiotherapy for patients with recurrent brain tumors unless there is biopsy proof of recurrent tumor</div>
<div class="sdl4">    - Prior radiosurgery within the past 9 months allowed provided there is documentation of progressive disease by biopsy, positron-emission tomography (PET) scan, or MR spectroscopy</div>
<div class="sdl4">    - No concurrent radiotherapy</div>
<div class="sdl4">    - More than 1 week since prior CYP3A4 inhibitors</div>
<div class="sdl4">    - More than 4 weeks since prior CYP3A4 inducers</div>
<div class="sdl4">    - More than 5 days since prior proton-pump inhibitors</div>
<div class="sdl4">    - More than 2 days since prior H_2 blockers</div>
<div class="sdl4">    - No prior erlotinib</div>
<div class="sdl4">    - No concurrent enzyme-inducing anticonvulsants</div>
<div class="sdl4">    - No concurrent proton-pump inhibitors</div>
<div class="sdl4">    - No concurrent H2 blockers</div>
<div class="sdl4">    - No other concurrent investigational agents</div>
<div class="sdl4">    - Concurrent antacids allowed provided the antacid is not administered 2 hours before, during, and 2 hours after erlotinib administration</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  21 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Regina Jakacki</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
</div><div class="sdl3 sds">&lt;agency&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m133B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m133&#39;)" style="display:none" /><img id="sdiff-collapse-m133B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m133&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m133B-cdiv" class="sdiff-collapsed" title="The middle 284 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m133&#39;)" style="display:none"></div><div id="sdiff-collapse-m133B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  1</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  56 days (2 courses)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  56 days (2 courses)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Pharmacokinetics of erlotinib hydrochloride</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At baseline and at 0.5, 1, 2, 4, 6, 8, and 24 hours of course 1</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Actual&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  95</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Previously Treated Childhood Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Brain Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Cerebellar Astrocytoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Cerebral Astrocytoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Ependymoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Malignant Germ Cell Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Medulloblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Soft Tissue Sarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Neuroblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Recurrent Osteosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  erlotinib hydrochloride</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Given orally (PO)</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  CP-358,774</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  erlotinib</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  OSI-774</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  temozolomide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Given PO</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  SCH 52365</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Temodal</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Temodar</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  TMZ</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  pharmacological study</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Correlative studies</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  pharmacological studies</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  laboratory biomarker analysis</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Correlative studies</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Treatment (erlotinib hydrochloride, temozolomide)</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria: </div>
<div class="sdl4">    - One of the following histologically confirmed solid tumors:            </div>
<div class="sdl4">    * Brain tumors</div>
<div class="sdl4">    * Osteogenic sarcoma</div>
<div class="sdl4">    * Rhabdomyosarcoma</div>
<div class="sdl4">    * Soft tissue sarcoma (excluding Ewing&amp;apos;s sarcoma)</div>
<div class="sdl4">    * Neuroblastoma</div>
<div class="sdl4">    * Germ cell tumors</div>
<div class="sdl4">    - Recurrent or refractory disease</div>
<div class="sdl4">    - No known curative therapy exists</div>
<div class="sdl4">    - Performance status - Karnofsky 50-100% (for patients age 11 to 21)</div>
<div class="sdl4">    - Performance status - Lansky 50-100% (for patients age 10 and under)</div>
<div class="sdl4">    - At least 8 weeks</div>
<div class="sdl4">    - Absolute neutrophil count &amp;gt; 1,000/mm^3</div>
<div class="sdl4">    - Platelet count &amp;gt; 100,000/mm^3 (transfusion independent*)</div>
<div class="sdl4">    - Hemoglobin &amp;gt; 8.0 g/dL (transfusion allowed)</div>
<div class="sdl4">    - Bilirubin &amp;lt; 1.5 times upper limit of normal (ULN)</div>
<div class="sdl4">    - ALT &amp;lt; 2.5 times ULN</div>
<div class="sdl4">    - Albumin &amp;#8805; 2 g/dL</div>
<div class="sdl4">    - Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min</div>
<div class="sdl4">    - Creatinine based on age as follows:            </div>
<div class="sdl4">    * &amp;#8804; 0.8 mg/dL for patients age 5 and under</div>
<div class="sdl4">    * &amp;#8804; 1.0 mg/dL for patients 6 to 10</div>
<div class="sdl4">    * &amp;#8804; 1.2 mg/dL for patients 11 to 15</div>
<div class="sdl4">    * &amp;#8804; 1.5 mg/dL for patients age 15 to 21</div>
<div class="sdl4">    - Not pregnant or nursing</div>
<div class="sdl4">    - Negative pregnancy test</div>
<div class="sdl4">    - Fertile patients must use effective contraception</div>
<div class="sdl4">    - Able to swallow tablets (for patients in part 2 only)</div>
<div class="sdl4">    - No uncontrolled infection</div>
<div class="sdl4">    - Recovered from all prior immunotherapy</div>
<div class="sdl4">    - At least 7 days since prior biologic therapy</div>
<div class="sdl4">    - At least 3 months since prior stem cell transplantation and no evidence of active graft-versus-host disease</div>
<div class="sdl4">    - More than 1 week since prior growth factors</div>
<div class="sdl4">    - No concurrent prophylactic growth factor therapy</div>
<div class="sdl4">    - No concurrent immunotherapy</div>
<div class="sdl4">    - No concurrent biologic therapy</div>
<div class="sdl4">    - More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered</div>
<div class="sdl4">    - No other concurrent chemotherapy</div>
<div class="sdl4">    - No concurrent systemic corticosteroids except for treatment of increased intracranial pressure or symptomatic tumor edema in patients with CNS tumors            </div>
<div class="sdl4">    * No concurrent steroids as an antiemetic</div>
<div class="sdl4">    - Concurrent dexamethasone for patients with CNS tumors allowed provided patient has been on a stable or decreasing dose for at least 1 week before study entry</div>
<div class="sdl4">    - Recovered from all prior radiotherapy</div>
<div class="sdl4">    - At least 2 weeks since prior local palliative radiotherapy (small port)</div>
<div class="sdl4">    - At least 6 weeks since prior substantial bone marrow irradiation</div>
<div class="sdl4">    - At least 6 months since prior craniospinal radiotherapy</div>
<div class="sdl4">    - At least 6 months since prior radiotherapy to 50% or more of the pelvis</div>
<div class="sdl4">    - At least 8 weeks since prior standard-fraction radiotherapy for patients with recurrent brain tumors unless there is biopsy proof of recurrent tumor</div>
<div class="sdl4">    - Prior radiosurgery within the past 9 months allowed provided there is documentation of progressive disease by biopsy, positron-emission tomography (PET) scan, or MR spectroscopy</div>
<div class="sdl4">    - No concurrent radiotherapy</div>
<div class="sdl4">    - More than 1 week since prior CYP3A4 inhibitors</div>
<div class="sdl4">    - More than 4 weeks since prior CYP3A4 inducers</div>
<div class="sdl4">    - More than 5 days since prior proton-pump inhibitors</div>
<div class="sdl4">    - More than 2 days since prior H_2 blockers</div>
<div class="sdl4">    - No prior erlotinib</div>
<div class="sdl4">    - No concurrent enzyme-inducing anticonvulsants</div>
<div class="sdl4">    - No concurrent proton-pump inhibitors</div>
<div class="sdl4">    - No concurrent H2 blockers</div>
<div class="sdl4">    - No other concurrent investigational agents</div>
<div class="sdl4">    - Concurrent antacids allowed provided the antacid is not administered 2 hours before, during, and 2 hours after erlotinib administration</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  21 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Regina Jakacki</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
</div><div class="sdl3 sds">&lt;agency&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m21"><td class="sdiff-h">21</td>
<td class="sdiff-a"><div class="sdl4"><span class="sdwd">Children&amp;apos;s</span> <span class="sdwd">Oncology</span> <span class="sdwd">Group</span>     </div>
</td>
<td class="sdiff-b"><div class="sdl4">   <span class="sdwa">COG</span> <span class="sdwa">Phase</span> <span class="sdwa">I</span> <span class="sdwa">Consortium</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m22"><td class="sdiff-h">22</td>
<td class="sdiff-a"><img id="sdiff-collapse-m420A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m420&#39;)" style="display:none" /><img id="sdiff-collapse-m420A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m420&#39;)" style="display:none" /><div class="sdl3 sdz">&lt;/agency&gt;</div>
<div id="sdiff-collapse-m420A-cdiv" class="sdiff-collapsed" title="The middle 5 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m420&#39;)" style="display:none"></div><div id="sdiff-collapse-m420A-ediv" class="sdiff-expanded"><div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2004-02-10</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m420B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m420&#39;)" style="display:none" /><img id="sdiff-collapse-m420B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m420&#39;)" style="display:none" /><div class="sdl3 sdz">&lt;/agency&gt;</div>
<div id="sdiff-collapse-m420B-cdiv" class="sdiff-collapsed" title="The middle 5 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m420&#39;)" style="display:none"></div><div id="sdiff-collapse-m420B-ediv" class="sdiff-expanded"><div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2004-02-10</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m23"><td class="sdiff-h">23</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2012-12-13</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2013-06-04</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m24"><td class="sdiff-h">24</td>
<td class="sdiff-a"><img id="sdiff-collapse-m428A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m428&#39;)" style="display:none" /><img id="sdiff-collapse-m428A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m428&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m428A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m428&#39;)" style="display:none"></div><div id="sdiff-collapse-m428A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m428B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m428&#39;)" style="display:none" /><img id="sdiff-collapse-m428B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m428&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m428B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m428&#39;)" style="display:none"></div><div id="sdiff-collapse-m428B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f121');
SDiffDeclareUnchCRID('sdiff-collapse-f133');
SDiffDeclareUnchCRID('sdiff-collapse-f420');
SDiffDeclareUnchCRID('sdiff-collapse-f427');
SDiffDeclareUnchCRID('sdiff-collapse-f45');
SDiffDeclareUnchCRID('sdiff-collapse-f457');
SDiffDeclareUnchCRID('sdiff-collapse-f473');
SDiffDeclareUnchCRID('sdiff-collapse-f64');
SDiffDeclareUnchCRID('sdiff-collapse-f91');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m121');
SDiffDeclareUnchCRID('sdiff-collapse-m133');
SDiffDeclareUnchCRID('sdiff-collapse-m420');
SDiffDeclareUnchCRID('sdiff-collapse-m428');
SDiffDeclareUnchCRID('sdiff-collapse-m45');
SDiffDeclareUnchCRID('sdiff-collapse-m64');
SDiffDeclareUnchCRID('sdiff-collapse-m91');
SDiffInit();
</script></body></html>